Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma

Inclusion Criteria: * Participants must have histologically or cytologic confirmed high grade dysplasia or cervical cancer. Histologic types include squamous cell, adenocarcinoma or adenosquamous cell carcinoma. * Participants must be eligible for surgical management with LEEP, CKC or hysterectomy or chemoradiation * Age ≥ 18 years * Normal liver function (AST, ALT, bilirubin within institutional normal limits). * Participants must be English speaking * Participants must have the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Participants with active liver disease, including primary biliary cirrhosis and unexplained, liver function abnormality * Participants with severe kidney impairment (CrCl ≤30 mL/min calculated using Cockcroft-Gault), or end-stage kidney disease on dialysis * Participants with preexisting gallbladder disease including active gallstones * Known hypersensitivity to fenofibrate or fenofibric acid * Participants that are pregnant or breast feeding due to unknown risk to developing fetus/infant. Please note: Participants of child-bearing potential (have had menses within the past year or have not had total hysterectomy) are actively screened for pregnancy prior to diagnostic procedures and screened again prior to treatment.